|
|
|
|
|
|||||||
|
Session 7
Oral Abstract Session
Opportunistic Infections and Complications of Antiretroviral Therapy Monday, 10 am - 12:30 pm 6E |
| Moderators | William Burman, Denver Public Hlth., CO and William Powderly, Washington Univ., Saint Louis, MO | ||
| 10:00 31. | An Objective Case Definition of HIV Lipodystrophy A. Carr* for the HIV Lipodystrophy Case Definition Study Group St. Vincent’s Hosp. and Univ. of New South Wales, Sydney, Australia
| ||
| 10:15 32. | Switching Stavudine or Zidovudine to Abacavir for HIV Lipoatrophy: A Randomised, Controlled, Open-Label, Multicentre, 24-Week Study A. Carr*1, D. Smith2, C. Workman3, J. Hoy4, N. Doong5, J. Amin2, M. Law2, D. A. Cooper1,2, and the MITOX Study Group 1St. Vincent's Hosp., Sydney; 2NCHECR, Univ. of New South Wales, Australia; 3AIDS Res. Initiative, Sydney; 4Alfred Hosp., Melbourne; and 5Burwood Road Med. Ctr., Sydney, Australia
| ||
| 10:30 33. | Prospective Study of Hyperlipidemia in ART-Naïve Subjects Taking Combivir/Abacavir (COM/ABC), COM/Nelfinavir (NFV), or Stavudine (d4T)/Lamivudine (3TC)/NFV (ESS40002) P. Kumar*1, A. Rodriguez-French 2, M. Thompson3, K. Tashima4, V. Williams5, P. Wannamaker5, and M. Shaefer5 1Georgetown Univ. Med. Ctr., Washington, DC; 2San Fernando Hosp., Panama City, Panama; 3AIDS Res. Consortium, Atlanta, GA; 4The Miriam Hosp., Providence, RI; and 5GlaxoSmithKline, Res. Triangle Park, NC
| ||
| 10:45 34. | Distinguishable Lipid Profiles between PI and NNRTI Therapy May Carry Different Risk of Cardiovascular Disease (CVD) F. van Leth*1, N. Friis-Møller2, R. Weber, A. d’Arminio Monforte, O. Kirk, R. Thiebaut, L. Morfeldt, C. Pradier, G. Calvo, M. Law, G. Bartsch, S. De Wit, C. Sabin, J. D. Lundgren2, and P. Reiss1 for the DAD Study Group 1ATHENA, Amsterdam, The Netherlands; and 2DAD Coordinating Ctr., Copenhagen, Denmark
| ||
| 11:00 35. | Incidence of Symptomatic Hyperlactatemia in HIV-Infected Adults on NRTIs J. T. Lonergan*, D. Havlir, E. Barber, and W. C. Mathews Univ. of California, San Diego
| ||
| 11:15 36. | Incidence of Grade IV Events, AIDS, and Mortality in a Large Multicenter Cohort Receiving HAART R. Reisler*1, C. Han2, W. Burman3, E. Tedaldi4, and J. Neaton2 1 NIAID,NIH, Bethesda, MD; 2 Univ. of Minnesota, Minneapolis; 3 Denver Publ. Hlth., CO; and 4 Temple Univ., Philadelphia, PA
| ||
| 11:30 37. | Safe Interruption of Maintenance Therapy (MT) against Prior Infection with 4 Common HIV-Associated Opportunistic Pathogens during Highly Active Antiretroviral Therapy O. Kirk1, P. Reiss2, C. Uberti-Foppa3, M. Bickel4, J. Gerstoft5, C. Pradier6, F. Wit2, B. Ledergerber7, J. D. Lundgren1, and H. Furrer8 for 7 European HIV cohorts. 1EuroSIDA, Copenhagen, Denmark; 2ATHENA, Amsterdam, Netherlands; 3HSR, Milan, Italy; 4Frankfurt HIV cohort, Germany; 5Danish cohort, Copenhagen, Denmark; 6DMI-2, Nice, France; and 7/8Swiss HIV cohort study, Zurich/Bern, Switzerland
| ||
| 11:45 38. | CMV and HIV Viral Burden and Development of CMV End-Organ Disease: a Prospective Study in HIV-Infected Subjects (ACTG 360) A. Erice*1, C. Tierney2, M. Hirsch2, A. Caliendo3, A. Weinberg4, M. Kendall2, and B. Polsky5 for the ACTG 360 Study Team 1Univ. of Minnesota, Minneapolis; 2Harvard Univ., Boston, MA; 3Emory Univ., Atlanta, GA; 4Univ. of Colorado, Denver; and 5Columbia Univ., New York, NY
| ||
| 12:00 39. | CMV Viraemia is an Independent Predictor of Disease Progression and Death in the Era of HAART J. Deayton *, C. Sabin, M. A. Johnson, V. Emery, and P. Griffiths Royal Free and Univ. Coll. Sch. of Med., London, UK
| ||
| 12:15 40. | Adipocyte-Derived Hormone Levels and their Corrlates in the HIV Lipodystrophy Syndrome L. Kosmiski, D. Kuritzkes, K. Lichtenstein, and R. Eckel Univ. of Colorado Hlth. Sci. Ctr., Denver
|
